What is the 13F Pro Quality Score for ALNY?

13F Pro ranks ALNYLAM PHARMACEUTICALS, INC. (ALNY) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ALNY's current score at https://13fpro.ai/research/ALNY (free sign-up required for the full ranking).

Which hedge funds own the most ALNY stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ALNY include FMR, Capital World Investors, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ALNY as soon as new 13F filings post.

Where does 13F Pro source ALNY data?

All ALNYLAM PHARMACEUTICALS, INC. fundamentals and ownership data come directly from SEC EDGAR. ALNYLAM PHARMACEUTICALS, INC. files with the SEC under CIK 1178670. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ALNY in?

ALNYLAM PHARMACEUTICALS, INC. (ALNY) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ALNY research updated on 13F Pro?

ALNY's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ALNYLAM PHARMACEUTICALS, INC.(ALNY)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1178670 ALNY stock profile & AI dashboard →

13F Pro Quality Score

60.9/100

Rank #825 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

89.3/100

Profitability

55.8/100

Balance Sheet

37.6/100

Earnings Quality

30.0/100

Free Cash Flow

66.8/100

Institutional Flow

65.5/100

Revenue Scale

70.5/100

Dilution Risk

17.6/100

ALNY Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ALNYLAM PHARMACEUTICALS, INC. (ALNY), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ALNY at 60.9/100 on a 32-signal composite quality model, placing it at rank #825 of 2,879 stocks — the top half of the AI-ranked universe. ALNY scores in the top quartile across revenue growth (89.3). Areas of concern include earnings quality (30.0) and balance sheet strength (37.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q4 2025), ALNYLAM PHARMACEUTICALS, INC. reports quarterly revenue of $1.1B, net income of $111.5M, an operating margin of 12.0%. Top institutional holders of ALNY by reported 13-F value include FMR, Capital World Investors, BlackRock,, based on the most recent SEC filings. ALNY trades on the Nasdaq exchange and files with the SEC under CIK 1178670. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALNY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ALNYLAM PHARMACEUTICALS, INC. directly from SEC EDGAR. ALNYLAM PHARMACEUTICALS, INC.'s 13F Pro composite quality score has ranged between 8 and 90 since 2021, currently 60.9 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about ALNYLAM PHARMACEUTICALS, INC.

Quirks, history, and lore behind ALNY — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · large-cap · listed on Nasdaq · headquartered in Cambridge, Massachusetts.
2
The Numbers
Annual revenue in the low billions of dollars, driven almost entirely by a handful of approved drugs — yet the company spent over a decade burning cash before its first product ever reached patients.
3
The History
Founded in 2002, the company was built from the ground up around a single Nobel Prize-winning biological mechanism discovered just a few years earlier: RNA interference.
4
The Secret
Its entire pipeline is built on silencing genes — using specially designed molecules to switch off the faulty genetic instructions that cause disease, rather than blocking the bad protein after the fact.
5
The Lore
Its landmark drug Onpattro was the first ever RNAi therapeutic approved anywhere in the world, making history in 2018 and validating a technology many had written off as science fiction.
6
The Giveaway
The pioneer of RNAi medicines, its approved drugs treat rare diseases like hereditary transthyretin amyloidosis — and its name is literally a portmanteau of "RNA" and "lam."

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q4 2025

$1.1B

Net Income

Q4 2025

$111.5M

Free Cash Flow

Q4 2025

$140.3M

Operating Margin

Q4 2025

12.0%

ROIC

Q4 2025

16.7%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+65.2% YoY

$3.71BFY 2025

FY21 $844.3MFY23 $1.83BFY24 $2.25BFY25 $3.71B

Net Income

+212.8% YoY

$313.7MFY 2025

FY21 $-852.8MFY23 $-440.2MFY24 $-278.2MFY25 $313.7M

Operating Income

+383.6% YoY

$501.6MFY 2025

FY21 $-708.7MFY23 $-282.2MFY24 $-176.9MFY25 $501.6M

EPS (Diluted)

+206.9% YoY

$2.33FY 2025

FY21 $-7.20FY23 $-3.52FY24 $-2.18FY25 $2.33

Total Assets

+17.1% YoY

$4.97BFY 2025

FY21 $3.64BFY23 $3.83BFY24 $4.24BFY25 $4.97B

Total Debt

—FY 2025

FY21 $675.7MFY23 —FY24 —FY25 —

Op. Cash Flow

+6405.1% YoY

$524.1MFY 2025

FY21 $-641.7MFY23 $104.2MFY24 $-8.3MFY25 $524.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2018	FY 2017
Revenue	$3.71B +65.2%	$2.25B +23.0%	$1.83B +116.5%	$844.3M +1027.1%	$74.9M +2483.0%	$2.9M
Net Income	$313.7M +212.8%	$-278.2M +36.8%	$-440.2M +48.4%	$-852.8M -12.0%	$-761.5M -55.1%	$-490.9M
Operating Income	$501.6M +383.6%	$-176.9M +37.3%	$-282.2M +60.2%	$-708.7M +13.0%	$-814.7M -62.9%	$-500.1M
EPS (Diluted)	$2.33 +206.9%	$-2.18 +38.1%	$-3.52 +51.1%	$-7.20	—	—
Total Assets	$4.97B +17.1%	$4.24B +10.7%	$3.83B +5.1%	$3.64B +131.3%	$1.57B -21.1%	$1.99B
Total Debt	—	—	—	$675.7M	—	—
Operating Cash Flow	$524.1M +6405.1%	$-8.3M -108.0%	$104.2M +116.2%	$-641.7M -14.1%	$-562.6M -47.0%	$-382.8M

AI Insight: ALNY Financial Trends

ALNY swung to significant profitability in Q3 2025 with $368M operating income and $251M net income, driven by a 149% revenue surge to $1,249M.

• Revenue accelerated sharply: $774M in Q2 2025 to $1,249M in Q3 2025 (61% sequential growth), suggesting major product ramp.

• Operating income turned decisively positive: $368M in Q3 2025 vs. $-16M in Q2 2025, reflecting operating leverage at scale.

• Operating cash flow improved: $325M in Q3 2025 vs. $154M in Q2 2025, demonstrating cash generation alongside profitability.

• Equity recovered to $789M in Q4 2025 from $-219M in Q1 2024, signaling strengthened balance sheet position.

⚠ Q4 2025 revenue declined 12% sequentially to $1,097M from Q3 peak—monitor whether this signals sustainability concerns or seasonal patterns.

⚠ Net income declined to $186M in Q4 2025 from $251M in Q3 2025 despite modest revenue decline; margin compression warrants tracking.

AI Insight: ALNY Ratio Trends

ALNY swung from Q2 2025 losses to Q4 2025 profitability, with operating margin rebounding to 12.0% and net margin to 17.0%.

• Operating margin improved from -2.1% in Q2 2025 to 29.5% in Q3 2025 and 12.0% in Q4 2025, signaling operational leverage.

• Net profit margin turned positive at 17.0% in Q4 2025 versus -8.6% in Q2 2025; TTM NPM now 8.5%.

• ROA recovered to 15.0% in Q4 2025 from -5.8% in Q2 2025; ROIC rebounded to 66.8% from -25.9% in Q2.

⚠ Q3 and Q4 2025 show strong momentum, but volatility across 2024–2025 (OpMargin ranged -17.7% to +29.5%) suggests execution risk.

⚠ TTM OpMargin of 13.5% masks Q4's 12.0% — monitor if recent quarter strength sustains or reverts.

Get alerted when ALNY's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ALNYLAM PHARMACEUTICALS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ALNY

FMR LLC
$4.8B14,579,166 sh
Capital World Investors
$3.6B10,802,348 sh
BlackRock, Inc.
$3.5B10,444,908 sh
Capital Research Global Investors
$3.1B9,471,181 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$2.1B6,491,280 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.0B5,946,706 sh
STATE STREET CORP
$1.1B3,322,698 sh
GEODE CAPITAL MANAGEMENT, LLC
$884.6M2,660,385 sh
BAILLIE GIFFORD & CO
$825.1M2,493,866 sh
TWO SIGMA INVESTMENTS, LP
$659.3M1,992,577 sh

Fund	Value	Shares
FMR LLC	$4.8B	14,579,166
Capital World Investors	$3.6B	10,802,348
BlackRock, Inc.	$3.5B	10,444,908
Capital Research Global Investors	$3.1B	9,471,181
VANGUARD PORTFOLIO MANAGEMENT LLC	$2.1B	6,491,280
VANGUARD CAPITAL MANAGEMENT LLC	$2.0B	5,946,706
STATE STREET CORP	$1.1B	3,322,698
GEODE CAPITAL MANAGEMENT, LLC	$884.6M	2,660,385
BAILLIE GIFFORD & CO	$825.1M	2,493,866
TWO SIGMA INVESTMENTS, LP	$659.3M	1,992,577

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ALNY on your watchlist

Track score changes the day ALNYLAM PHARMACEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ALNY a good stock to buy?

13F Pro's AI-powered analysis of ALNYLAM PHARMACEUTICALS, INC. (ALNY) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ALNY are available on the ALNY stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ALNY?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ALNY. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ALNYLAM PHARMACEUTICALS, INC.'s investment landscape.